Amulirafusp Biosimilar – Anti-Leukocyte surface antigen CD47 fusion protein – Research Grade

Introduction

Amulirafusp Biosimilar is a therapeutic protein that has recently gained attention in the field of cancer research. It is a biosimilar version of the anti-leukocyte surface antigen CD47 fusion protein, which has shown promising results in preclinical studies as a potential treatment for various types of cancer. In this article, we will discuss the structure, activity, and potential applications of Amulirafusp Biosimilar.

Structure of Amulirafusp Biosimilar

Amulirafusp Biosimilar is a fusion protein that consists of two components: the extracellular domain of the CD47 receptor and a humanized immunoglobulin G1 Fc fragment. The CD47 receptor is a transmembrane protein that is expressed on the surface of various cell types, including cancer cells. The Fc fragment is responsible for binding to the Fc receptors on immune cells, such as macrophages, and triggering their activation.

Activity of Amulirafusp Biosimilar

The main activity of Amulirafusp Biosimilar is its ability to block the interaction between CD47 and its ligand, signal regulatory protein alpha (SIRPα). This interaction is known to play a crucial role in immune evasion by cancer cells. By blocking this interaction, Amulirafusp Biosimilar promotes the recognition and elimination of cancer cells by the immune system, leading to tumor regression.

In addition, the Fc fragment of Amulirafusp Biosimilar also has a direct cytotoxic effect on cancer cells. This is achieved through the activation of immune cells, such as macrophages and natural killer cells, which release cytotoxic molecules that can directly kill cancer cells.

Therapeutic Target

The therapeutic target of Amulirafusp Biosimilar is the CD47 receptor, which is overexpressed on the surface of various cancer cells. CD47 is known to play a crucial role in immune evasion by cancer cells, making it an attractive target for cancer therapy. By blocking the CD47-SIRPα interaction, Amulirafusp Biosimilar can restore the ability of the immune system to recognize and eliminate cancer cells.

Application of Amulirafusp Biosimilar

Amulirafusp Biosimilar has shown promising results in preclinical studies as a potential treatment for various types of cancer, including breast cancer, ovarian cancer, and acute myeloid leukemia. It has also been shown to enhance the efficacy of other cancer treatments, such as chemotherapy and radiotherapy.

In addition to its potential as a cancer therapy, Amulirafusp Biosimilar may also have applications in other diseases where CD47 is overexpressed, such as autoimmune disorders and cardiovascular diseases. Further research is needed to explore these potential applications.

Conclusion

In conclusion, Amulirafusp Biosimilar is a promising therapeutic protein that has the potential to revolutionize cancer treatment. Its unique structure and activity make it a potent inhibitor of the CD47-SIRPα interaction, leading to the recognition and elimination of cancer cells by the immune system. With ongoing research and clinical trials, Amulirafusp Biosimilar may soon become a valuable addition to the arsenal of cancer therapies.

ProteoGenix catalogue number PX-TA2223. For research use only.

Target: Amulirafusp Biosimilar – Anti-Leukocyte surface antigen CD47 fusion protein – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet